4-Methoxysalicylic Acid

4-Methoxysalicylic Acid

SCHEMBL483346

COc1ccc(C(=O)O)c(O)c1

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.75
RAB9A P51151 4/20 0.75
HPGD P15428 3/20 0.72
ALDH1A1 P00352 3/20 0.72
MAPK1 P28482 3/20 0.72
CYP3A4 P08684 3/20 0.72
LMNA P02545 4/20 0.67
CYP2C19 P33261 3/20 0.67
CYP1A2 P05177 2/20 0.67
PGR P06401 2/20 0.67
SLC6A2 P23975 2/20 0.67
CYP2D6 P10635 1/20 0.67
PDE4A P27815 1/20 0.67
HRH1 P35367 1/20 0.67
HTT P42858 1/20 0.67
SLC6A3 Q01959 1/20 0.67
PDE4D Q08499 1/20 0.67
ADORA3 P0DMS8 1/20 0.64
AR P10275 1/20 0.64
CHRM1 P11229 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Methoxysalicylic Acid SCHEMBL3212873 0.98 NPC1 (0.72) NPC1RAB9AHPGDALDH1A1MAPK1
4-Methoxysalicylic Acid SCHEMBL15271279 0.98 NPC1 (0.72) NPC1RAB9AHPGDALDH1A1MAPK1
4-Methoxysalicylic Acid SCHEMBL3212855 0.98 NPC1 (0.72) NPC1RAB9AHPGDALDH1A1MAPK1
4-Methoxysalicylic Acid SCHEMBL30490367 0.98 NPC1 (0.72) NPC1RAB9AHPGDALDH1A1MAPK1
4-Methoxysalicylic Acid SCHEMBL15271283 0.98 NPC1 (0.72) NPC1RAB9AHPGDALDH1A1MAPK1
4-Methoxysalicylic Acid SCHEMBL30179513 0.98 NPC1 (0.72) NPC1RAB9AHPGDALDH1A1MAPK1
SCHEMBL10596186 0.89 NPC1 (0.61) NPC1RAB9AHPGDALDH1A1MAPK1
SCHEMBL29365072 0.86 NPC1 (1.00) NPC1RAB9AHPGDALDH1A1MAPK1
SCHEMBL38652 0.86 NPC1 (1.00) NPC1RAB9AHPGDALDH1A1MAPK1
SCHEMBL1514997 0.86 NPC1 (1.00) NPC1RAB9AHPGDALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1894 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122031539-A Pine bark polyphenol extract and preparation method and application thereof 北京农学院 2026-05-15 CN claimed
CN-122005693-A Application of Jiaweidanzhi Xiaoyao powder or extract thereof in preparation of medicines for treating depression complicated with ulcerative colitis 河南中医药大学 2026-05-12 CN claimed
US-20260092029-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE SCRIPPS RESEARCH INST (US) 2026-04-02 US claimed
US-20260002924-A1 METHOD FOR SELECTING ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS FROM MIXTURE OF ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS AND OTHER TYPES OF POLYMERS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2026-01-01 US claimed
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
US-12383476-B2 W/O/W emulsion composition SHISEIDO COMPANY, LTD. (JP) 2025-08-12 US claimed
EP-4584236-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE The Scripps Research Institute (US) 2025-07-16 EP claimed
US-20250214921-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND KAO CORPORATION (JP) 2025-07-03 US claimed
CN-118880486-B Cool polyester fiber and preparation method thereof 江苏恒科新材料有限公司 2025-06-24 CN claimed
CN-119591965-B Heat-resistant polyethylene material and preparation method thereof 北京市科学技术研究院 2025-05-16 CN claimed
WO-2003077861-A2 WATER-BASED DELIVERY SYSTEMS COLLAGENEX PHARMACEUTICALS, INC. (US) 2003-09-25 WO claimed
US-20030130300-A1 Respiratory system disorders; synergistic mixtures BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-10 US claimed
WO-2003024452-A1 NOVEL MEDICAMENTS FOR INHALATION BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-03-27 WO claimed
US-20020128310-A1 MEDICAL COMPOSITION AND USE THEREOF FOR THE MANUFACTURE OF A TOPICAL BARRIER FORMULATION, A UV-RADIATION ABSORBING FORMULATION, OR AN ANTIVIRAL, ANTIFUNGAL, OR ANTIINFLAMMTORY FORMULATION NOVISCENS AB (SE) 2002-09-12 US claimed
EP-0957927-A1 MEDICAL COMPOSITION AND USE THEREOF FOR THE MANUFACTURE OF A TOPICAL BARRIER FORMULATION, A UV-RADIATION ABSORBING FORMULATION, OR AN ANTIVIRAL, ANTIFUNGAL, OR ANTIINFLAMMATORY FORMULATION Noviscens AB (SE) 1999-11-24 EP claimed
EP-0534817-B1 Esterification process of salts of carboxylic acids RHODIA CHIMIE SA (FR) 1998-12-09 EP claimed
WO-1998026788-A1 MEDICAL COMPOSITION AND USE THEREOF FOR THE MANUFACTURE OF A TOPICAL BARRIER FORMULATION, A UV-RADIATION ABSORBING FORMULATION, OR AN ANTIVIRAL, ANTIFUNGAL, OR ANTIINFLAMMATORY FORMULATION NOVISCENS AB (SE) 1998-06-25 WO claimed
EP-0539274-B1 Method for the synthesis of aldehydes and of their derivatives RHONE POULENC CHIMIE (FR) 1996-04-10 EP claimed
US-4141774-A METHOXYMETHYLATED NYLON TERPOLYMER DAICEL LTD. (JP) 1979-02-27 US claimed
US-3932340-A ACID CATALYSTS DAICEL LTD. (JA) 1976-01-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092029-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE CYP2B6, CYP2A6, CYP1A1 NPC1 3490/4885RAB9A 4623/4885HPGD 110/4885
US-20260002924-A1 METHOD FOR SELECTING ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS FROM MIXTURE OF ESTER FUNCTIONAL GROUP-CONTAINING POLYMERS AND OTHER TYPES OF POLYMERS FGB, NR4A1, CYP2E1 NPC1 1136/4885RAB9A 4242/4885HPGD 2585/4885
US-20250214921-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND HSD17B7, HSD17B12, BCKDK NPC1 2341/4885RAB9A 4512/4885HPGD 441/4885
US-20030130300-A1 Respiratory system disorders; synergistic mixtures ADRB3, ADRB1, CHRM3 NPC1 3159/4885RAB9A 651/4885HPGD 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.